DOCSLIB.ORG

Discovery Awaits You at the 81ST Scientific Sessions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Discovery Awaits You at the 81ST Scientific Sessions VIRTUAL | JUNE 25–29, 2021 Discovery awaits you at the ST 81 Scientific Sessions Final Program scientificsessions.diabetes.org #ADA2021 THE RIGHT SOLUTION AT THE RIGHT TIME View The Scientific Sessions Closed-Loop Increases Time-in-Range Glycemic outcomes of new InPen™ Durable insulin pumps vs. multiple daily in Older Adults with Type 1 Diabetes smart insulin pen users who injections for type 1 diabetes: Healthcare Compared with Sensor-Augmented received virtual onboarding utilization and A1C Pump Therapy: A Randomized Smith | ePoster Shah | ePoster Crossover Trial Patient Reported Satisfaction During Infusion Set Survival and Performance McAuley | Oral | Sun. 6/27 @ 4:30 pm the Medtronic Extended-Wear During the Medtronic Extended-Wear Infusion Set (EWIS) Pivotal Trial Infusion Set (EWIS) Pivotal Trial Impact of InPen™ smart insulin pen use Brazg | ePoster Buckingham | ePoster on real-world glycemic and insulin Preclinical study of a combined Robust glycemic outcomes after MiniMed™ dosing outcomes in individuals with insulin infusion and glucose sensing Advanced Hybrid Closed-Loop (AHCL) poorly controlled diabetes device (DUO) System use regardless of previous therapy Vigersky | Oral | Sun. 6/27 @ 6:15 pm Zhang | ePoster Shin | ePoster Visit Our Virtual Exhibit https://www.medtronic.com/diabetes-exhibit to find more information on: Smart MDI Therapy Insulin Pump Therapy Personalized Service Stay on Track with the First Automated Insulin Delivery & Support Smart MDI System* for Improved Glucose Control Always By Your Side View Our Presentations Product Theater: Shared Decision With Diabetes Technology Friday, June 25, 2021 | 10:00 – 11:00 am ET The introduction of smart insulin pens is bringing the vast majority of people on insulin injection therapy into the digital age. Learn about the rapidly changing insulin delivery landscape including research showing how automated insulin delivery systems are reducing the burden of insulin management while improving outcomes. Janice MacLeod, MA, Diana Isaacs, PharmD, Robert Vigersky, MD Ali Dianaty RD, CDCES, FADCES BCPS, BC-ADM, Chief Medical Officer, VP Product Innovation, Clinical Advocacy, CDCES, FADCES Medtronic Diabetes Medtronic Diabetes Medtronic Diabetes Cleveland Clinic Learning Byte #1: Learning Byte #2: Transitioning From MDI To MiniMed™ 770G System Inpen™ Smart Insulin Pen: Product Features and Overview Laurie Jung, RD, CDCES Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES Medtronic Diabetes Cleveland Clinic *Smart insulin pens connect to a mobile app to provide dosing calculations, reminders and CGM system integration. Important Safety Information for MiniMed™ 770G System: The MiniMed™ 770G system is for type 1 ages 2 and over. Prescription required. Individual results may vary. WARNING: Do not use SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of insulin/day. For details, please visit http://www.medtronicdiabetes.com/support/download-library/user-guides and www.medtronicdiabetes.com/importantsafetyinformation for complete details. Important Safety Information for InPenTM The InPen is a home-use reusable pen injector for single-patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection of a desired dose of insulin and for calculating an insulin dose or carbohydrate intake based on user entered data. A healthcare professional must assist in dosage programming of the device prior to use, based on various patient-specific criteria and targets. The InPen requires a prescription. For additional product and safety information, see User Guide and http://bit.ly/InPenSafety. US-DBA-2100192 © 2021 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. AMERICAN DIABETES ASSOCIATION Final Program 81st Virtual Scientific Sessions June 25-29 The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. ©2021 American Diabetes Association Table of Contents Day-At-A-Glance Schedule Friday, June 25……………………………………………………………………………………………………………………………………………………………………2-3 Saturday, June 26……………………………………………………………………………………………………………………………………………………………….4-5 Sunday, June 27………………………………………………………………………………………………………………………………………………………………….6-7 Monday, June 28………………………………………………………………………………………………………………………………………………………………..8-9 Tuesday, June 29………………………………………………………………………………………………………………………………………………………………….10 Abstracts Abstract Embargo Policy..............................................................................................................................................................1 Oral Presentations.........................................................22-27, 33, 39-45, 49-55, 58-67, 73-77, 82-84, 88-95, 101-104, 107-113 General Poster Session Category Ranges………………………………………………………………………………………………………………….…119-121 Poster Session Titles....................................................................................................................................................……122-199 Late Breaking Poster Session Titles……………………………………………………………………………………………………………………………..200-221 Program Information Friday, June 25......................................................................................................................................................................11-27 Saturday, June 26.................................................................................................................................................................28-55 Sunday, June 27....................................................................................................................................................................56-84 Monday, June 28................................................................................................................................................................85-114 Tuesday, June 29..............................................................................................................................................................115-118 Abstract Embargo Policy All meeting attendees, members of the media, companies, institutions, organizations, universities, investment advisors, and all other individuals are required to abide by the embargo policy governing the ADA’s 81st Scientific Sessions. An embargo means that information from any abstract or presentation is confidential and may not be announced, publicized, or distributed before the embargo date and time. This policy applies to all formats of release, including the Scientific Sessions online itinerary planner, meeting app, abstracts published on the journal Diabetes® website, and any other distribution method. Specific Embargo Dates and Times: *Oral Presentations: Abstracts selected for oral presentation are embargoed from the time of submission until conclusion of the presentation at the 81st Scientific Sessions. The ADA reserves the right to adjust the embargo as needed. *Poster Presentations: Abstracts selected for poster presentation are embargoed from the time of submission until Friday, June 25, 2021 at 11:30 a.m. U.S. Eastern Time Published Only: Abstracts selected for Published Only are embargoed from the time of submission until Friday, June 25, 2021 at 11:30 a.m. U.S. Eastern Time. *Abstracts included in the ADA’s official 81st Scientific Sessions Press Program are embargoed from the time of submission until conclusion of the News Briefing in which the research is presented or until conclusion of the presentation at the 81st Scientific Sessions, whichever is first. Please contact the ADA Press Office if you have any questions at [email protected]. Abstract Availability: Embargoed text of abstracts will be made available online on Tuesday, June 22, 2021. Note: The abstract embargo still applies; however, abstracts are made available to attendees to assist in creating their itineraries for the meeting. 1 Virtual Exhibits and Poster Hall: Available beginning at 11:30 a.m. DAY-AT-A-GLANCE SCHEDULE FRIDAY, JUNE 25, 2021 Behavioral Medicine, Acute and Chronic Clinical Nutriti on, Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Acti on/ Integrated Islet Biology/ Complicati ons Educati on, and Exercise Therapeuti cs Geneti cs Transplantati on Molecular Metabolism Physiology/Obesity Insulin Secreti on 11:30 a.m.- Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium 12:30 p.m. The Impact of COVID-19 on Executi ve Functi on in Youth Diabetes Preventi on in Resources for Interpreti ng Dietary Modulati on of The Bile Acid Receptor FXR Debate—What’s the Foot Care in Diabetes with Type 1 Diabetes— Vulnerable Populati ons Geneti c Variants Nutrient Metabolism in and the Microbiome Hubbub about Beta-Cell Driven to Diabetes Associated with Diabetes Cancer Hubs? Mini-Symposium Distracti on Mini-Symposium and Obesity Intersecti on of Diabetes, COVID-19, Diabetes, and Heart Failure, and Kidney Mini-Symposium Pregnancy—The Perfect Disease—Challenges and The Anatomy of Inter- Storm? New Insights (Includes disciplinary Integrati on in Live Video Questi on and Health Care Educati on Answer Period) Mini-Symposium Mini-Symposium Carbohydrate Intake and Could Point-of-Care Its Impact on Athleti cs and Devices Prove Useful in Health—A Debate the Diagnosis of Diabeti c Neuropathy in Clinical Practi ce? 12:45 p.m.- Mini-Symposium
Load more

Recommended publications
  • Dapagliflozin – Structure, Synthesis, and New Indications
    Pharmacia 68(3): 591–596 DOI 10.3897/pharmacia.68.e70626 Review Article Dapagliflozin – structure, synthesis, and new indications Stefan Balkanski1 1 Bulgarian Pharmaceutical Union, Sofia, Bulgaria Corresponding author: Stefan Balkanski ([email protected]) Received 24 June 2021 ♦ Accepted 4 July 2021 ♦ Published 4 August 2021 Citation: Balkanski S (2021) Dapagliflozin – structure, synthesis, and new indications. Pharmacia 68(3): 591–596.https://doi. org/10.3897/pharmacia.68.e70626 Abstract Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitors used in the treatment of patients with type 2 diabetes. An aryl glycoside with significant effect as glucose-lowering agents, Dapagliflozin also has indication for patients with Heart Failure and Chronic Kidney Disease. This review examines the structure, synthesis, analysis, structure activity relationship and uses of the prod- uct. The studies behind this drug have opened the doors for the new line of treatment – a drug that reduces blood glucoses, decreases the rate of heart failures, and has a positive effect on patients with chronic kidney disease. Keywords Dapagliflozin, SGLT2-inhibitor, diabetes, heart failure Structure of dapagliflozin against diabetes (Lee et al. 2005; Lemaire 2012; Mironova et al. 2017). Embodiments of (SGLT-2) inhibitors include C-glycosides have a remarkable rank in medicinal chemis- dapagliflozin, canagliflozin, empagliflozin and ipragliflozin, try as they are considered as universal natural products shown in Figure 1. It has molecular formula of C24H35ClO9. (Qinpei and Simon 2004). Selective sodium-dependent IUPAC name (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4- glucose cotransporter 2 (SGLT-2) inhibitors are potent ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxa- medicinal candidates of aryl glycosides that are functional ne-3,4,5-triol;(2S)-propane-1,2-diol;hydrate.
    [Show full text]
  • Israel Resource Cards (Digital Use)
    WESTERN WALL ַה ּכֹו ֶתל ַה ַּמ ַעָר ִבי The Western Wall, known as the Kotel, is revered as the holiest site for the Jewish people. A part of the outer retaining wall of the Second Temple that was destroyed by the Romans in 70 CE, it is the place closest to the ancient Holy of Holies, where only the Kohanim— —Jewish priests were allowed access. When Israel gained independence in 1948, Jordan controlled the Western Wall and all of the Old City of Jerusalem; the city was reunified in the 1967 Six-Day War. The Western Wall is considered an Orthodox synagogue by Israeli authorities, with separate prayer spaces for men and women. A mixed egalitarian prayer area operates along a nearby section of the Temple’s retaining wall, raising to the forefront contemporary ideas of religious expression—a prime example of how Israel navigates between past and present. SITES AND INSIGHTS theicenter.org SHUK ׁשוּק Every Israeli city has an open-air market, or shuk, where vendors sell everything from fresh fruits and vegetables to clothing, appliances, and souvenirs. There’s no other place that feels more authentically Israeli than a shuk on Friday afternoon, as seemingly everyone shops for Shabbat. Drawn by the freshness and variety of produce, Israelis and tourists alike flock to the shuk, turning it into a microcosm of the country. Shuks in smaller cities and towns operate just one day per week, while larger markets often play a key role in the city’s cultural life. At night, after the vendors go home, Machaneh Yehuda— —Jerusalem’s shuk, turns into the city’s nightlife hub.
    [Show full text]
  • Supplementary Material
    Supplementary material Table S1. Search strategy performed on the following databases: PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL). 1. Randomi*ed study OR random allocation OR Randomi*ed controlled trial OR Random* Control* trial OR RCT Epidemiological study 2. sodium glucose cotransporter 2 OR sodium glucose cotransporter 2 inhibitor* OR sglt2 inhibitor* OR empagliflozin OR dapagliflozin OR canagliflozin OR ipragliflozin OR tofogliflozin OR ertugliflozin OR sotagliflozin OR sergliflozin OR remogliflozin 3. 1 AND 2 1 Table S2. Safety outcomes of empagliflozin and linagliptin combination therapy compared with empagliflozin or linagliptin monotherapy in treatment naïve type 2 diabetes patients Safety outcome Comparator 1 Comparator 2 I2 RR [95% CI] Number of events Number of events / / total subjects total subjects i. Empagliflozin + linagliptin vs empagliflozin monotherapy Empagliflozin + Empagliflozin linagliptin monotherapy ≥ 1 AE(s) 202/272 203/270 77% 0.99 [0.81, 1.21] ≥ 1 drug-related 37/272 38/270 0% 0.97 [0.64, 1.47] AE(s) ≥ 1 serious AE(s) 13/272 19/270 0% 0.68 [0.34, 1.35] Hypoglycaemia* 0/272 5/270 0% 0.18 [0.02, 1.56] UTI 32/272 25/270 29% 1.28 [0.70, 2.35] Events suggestive 12/272 13/270 9% 0.92 [0.40, 2.09] of genital infection i. Empagliflozin + linagliptin vs linagliptin monotherapy Empagliflozin + Linagliptin linagliptin monotherapy ≥ 1 AE(s) 202/272 97/135 0% 1.03 [0.91, 1.17] ≥ 1 drug-related 37/272 17/135 0% 1.08 [0.63, 1.84] AE(s) ≥ 1 serious AE(s) 13/272 2/135 0% 3.22 [0.74, 14.07] Hypoglycaemia* 0/272 1/135 NA 0.17 [0.01, 4.07] UTI 32/272 12/135 0% 1.32 [0.70, 2.49] Events suggestive 12/272 4/135 0% 1.45 [0.47, 4.47] of genital infection RR, relative risk; AE, adverse event; UTI, urinary tract infection.
    [Show full text]
  • Therapeutic Potential for Coxibs-Nitric Oxide Releasing Hybrids in Cystic fibrosis
    European Journal of Medicinal Chemistry xxx (xxxx) xxx Contents lists available at ScienceDirect European Journal of Medicinal Chemistry journal homepage: http://www.elsevier.com/locate/ejmech Research paper Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis Sara Consalvi a, Giovanna Poce a, Carla Ghelardini b, Lorenzo Di Cesare Mannelli b, Paola Patrignani c, Annalisa Bruno c, Maurizio Anzini d, Vincenzo Calderone e, * Alma Martelli e, Lara Testai e, Antonio Giordani f, Mariangela Biava a, a Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy b Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Via Schiff 6, Sesto Fiorentino, 50019, Florence, Italy c Department of Neuroscience, Imaging and Clinical Sciences, And Center for Advanced Studies and Technology (CAST), School of Medicine, G. D’Annunzio University, Chieti, Italy d Department of Biotechnology, Chemistry, And Pharmacy, DoE 2018-2022, University of Siena, 53100, Siena, Italy e Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy f Formerly Rottapharm at the Present Consultant, Italy article info abstract Article history: This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO- Received 4 June 2020 Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research Received in revised form group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among 27 October 2020 them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. Accepted 28 October 2020 The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.
    [Show full text]
  • Download Article
    Advances in Social Science, Education and Humanities Research, volume 324 International Conference on Architecture: Heritage, Traditions and Innovations (AHTI 2019) Exploration on the Protection Scheme of the Great Ruins of Southern Lifang District in the Luoyang City Site in Sui and Tang Dynasties Haixia Liang Luoyang Institute of Science and Technology Luoyang, China Peiyuan Li Zhenkun Wang Xi’an University of Architecture and Technology China Petroleum First Construction Company (Luoyang) Xi'an, China Luoyang, China Abstract—The great ruins are a kind of non-renewable district in a comprehensive and detailed way. Through the precious resources. The southern Lifang district in the analysis of the current situation of southern Lifang district, a Luoyang City Site in Sui and Tang Dynasties is the product of relatively reasonable planning proposal is obtained. This the development of ancient Chinese capital to a certain study can provide theoretical or practical reference and help historical stage. As many important relics and rich cultural on the protection and development of Luoyang City Site in history have been excavated here, the district has a rich Sui and Tang Dynasties, as well as the reconstruction of humanity history. In the context of the ever-changing urban southern Lifang district. construction, the protection of the great ruins in the district has become more urgent. From the point of view of the protection of the great ruins, this paper introduces the II. GREAT RUINS, SUI AND TANG DYNASTIES, LUOYANG important sites and cultural relics of southern Lifang district CITY AND LIFANG DISTRICT in Luoyang city of the Sui and Tang Dynasties through field Great ruins refer to large sites or groups of sites with a investigation and literature review.
    [Show full text]
  • Download the Program
    The first International Congress of Neuroimmunology was held in Stresa, Italy, in 1982 and wasThe organized first International by Drs. Peter Congress O. Behan of Neuroimmunology and Federico Spreafico. was held The in secondStresa, Italy,International in Congress1982 and of wasNeuroimmunology organized by Drs. was Peter held O.in Philadelphia,Behan and Federico PA, and Spreafico. was organised The second by C.S. Raine andInternational Dale E. McFarlin. Congress It was of atNeuroimmunology this meeting in Philadelphiawas held in inPhiladelphia, 1987 that itPA, was and decided was to startorganised an international by C.S. Raine society, and the Dale International E. McFarlin. Society It was ofat Neuroimmunology,this meeting in Philadelphia and an election wasin 1987held forthat a it panel was decided of officers. to start C.S. anRaine international was elected society, President, the International John Newson-Davis Society Vice President,of Neuroimmunology, Robert Lisak andTreasurer an election and Kenethwas held Johnson for a panel Secretary, of officers. together Cedric with S. an InternationalRaine was Advisoryelected President,Board. The John Society Newson-Davis was incorporated Vice President,in 1988. Subsequent Robert Lisak meetings wereTreasurer in Jerusalem and Kenneth 1991 (Oder Johnson Abramsky Secretary, and togetherHaim Ovadia), with Amsterdaman International 1994 (KeeAdvisory Lucas), Board. Montreal 1998 (Jack Antel and Trevor Owens), Edinburgh 2001 (John Greenwood,The Society Sandra was Amor,incorporated David Baker, in 1988.John
    [Show full text]
  • Acute Renal Failure in Patients with Type 1 Diabetes Mellitus G
    Postgrad Med J: first published as 10.1136/pgmj.70.821.192 on 1 March 1994. Downloaded from Postgrad Med J (1994) 70, 192- 194 C) The Fellowship of Postgraduate Medicine, 1994 Acute renal failure in patients with type 1 diabetes mellitus G. Woodrow, A.M. Brownjohn and J.H. Turney Renal Unit, Leeds General Infirmary, Great George Street, Leeds LSJ 3EX, UK Summary: Acute renal failure (ARF) is a serious condition which still carries a mortality of around 50%. People with diabetes may be at increased risk of developing ARF, either as a complication of diabetic ketoacidosis or hyperosmolar coma, increased incidence of cardiovascular disease, or due to increased susceptibility ofthe kidney to adverse effects in the presence ofunderlying diabetic renal disease. During the period 1956-1992, 1,661 cases of ARF have been treated at Leeds General Infirmary. Of these, we have identified 26 patients also having type 1 diabetes. ARF due to diabetic ketoacidosis is surprisingly uncommon (14 cases out of 23 patients whose notes were reviewed). All cases of ARF complicating ketoacidosis in the last decade have been associated with particularly severe illness requiring intensive care unit support, rather than otherwise 'uncomplicated' ketoacidosis. We discuss the conditions that may result in ARF in patients with diabetes and the particular difficulties that may be encountered in management. Introduction People with diabetes may be at increased risk of Results developing acute renal failure (ARF). Acute pre- copyright. renal failure may occur as a result ofthe severe fluid Of 23 patients with type 1 diabetes complicated by depletion associated with diabetic ketoacidosis and ARF, diabetic ketoacidosis was the main underly- non-ketotic hyperosmolar coma.
    [Show full text]
  • CONNECTED APART Winter 2021
    CONNECTED APART Winter 2021 1 COMPOSE YOUR FUTURE qhere World-class faculty. State-of-the-art facilities you have to see (and hear) to believe. Endless performance and academic possibilities. All within an affordable public university setting ranked the number five college town in America.* Come see for yourself how the University of Iowa School of Music composes futures...one musician at a time. To apply, or for more information, visit music.uiowa.edu. *American Institute for Economic Research, 2017 MUSIC.UIOWA.EDU WINTER 2021 VIRTUAL PERFORMANCES The past year has been difficult for everyone, and we know that for many families, incomes have been reduced or become more unpredictable. To ensure that every CYSO family—no matter their CYSO is investing in the future of music and the financial situation—can enjoy our virtual performances, we've next generation of leaders. We provide music replaced our normal ticketing with a pay-what-you-can donation. education to nearly 800 young musicians ages 6-18 through full and string orchestras, jazz, CYSO virtual winter performances will debut on Saturday, steelpan, chamber music, masterclasses, music March 27, 2021 at 7:00 pm CST. For those who are able, the suggested donation is $40 (the equivalent of $10 per tick- composition and in-school programs. Students et for a family of four) to access all winter performance videos. learn from some of Chicago’s most respected Visit cyso.org/concerts to purchase your tickets. If you cannot professional musicians, perform in the world’s afford a ticket donation at this time, simply fill out the form with a great concert halls, and gain skills necessary for $0 amount to receive the performance link at no charge.
    [Show full text]
  • Effect of Biochemical Parameters Showing Atherogenicity in Type 2 Diabetic Nephropathy
    International Journal of Basic and Applied Chemical Sciences ISSN: 2277-2073 (Online) An Online International Journal Available at http://www.cibtech.org/jcs.htm 2012 Vol. 2 (4) October-December pp.26-30/Raja and Shaker Research Article EFFECT OF BIOCHEMICAL PARAMETERS SHOWING ATHEROGENICITY IN TYPE 2 DIABETIC NEPHROPATHY *G. Raja and Ivvala Anand Shaker *Department of Biochemistry, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur-603319, Tamil Nadu, India *Author for Correspondence ABSTRACT Diabetic nephropathy is one of the major complications of diabetes mellitus characterized by frequent microalbuminuria, elevated arterial blood pressure, a persistent decline in glomerular filtration rate and a high risk of cardiovascular morbidity and mortality. The study comprised of 30 Diabetic mellitus (DM) with microalbuminuria patients (Group 3), 30 DM without microalbuminuria patients (group 2) compared with 30 healthy controls (Group 1). Fasting glucose, post prandial glucose, lipid profile, fructosamine and microalbuminuria were investigated in all the groups. The significant increase in serum fructosamine, fasting and post prandial glucose levels along with increased microalbuminuria observed in group 3 patients compared to group 2 and group 1 patients. Hyperglycemia, increased fructosamine and increased Cholesterol, triglycerides with decreased HDL-cholesterol levels indicates the major risk of atherogenicity. Key Words: Diabetic nephropathy, Microalbuminuria, Fructosamine and Atherogenicity INTRODUCTION Diabetes mellitus (DM) is a disease in which the hallmark feature is elevated blood glucose concentrations due to loss of insulin-producing pancreatic β-cells (type 1 diabetes) or through loss of insulin responsiveness in its target tissues (type 2 diabetes). Type 1 diabetes usually begins to manifest in childhood and early adulthood, but type 2 diabetes is typically a disease for which increased age is a risk factor (Schwarz, 2009).
    [Show full text]
  • High Court of Karnataka, Bengaluru
    HIGH COURT OF KARNATAKA, BENGALURU DISTRICT JUDICIARY ADMINISTRATION BRANCH - I FINAL SENIORITY LIST OF SHERISTEDARS OF DISTRICT JUDICIARY IN THE STATE FROM 01.04.1978 TO 12.07.2019. Date of Local Retirement/ Ca Cadre/ Date of Entry Date of Entry Date of Deemed Date Voluntary te Residu Sl. No. Name of the Official District Date of Birth into Feeder Remarks into Service Promotion of Promotion Retiremetn/ go al Cadre (FDA) Resignation/ ry Parent Dismissal Cadre 1 K GUNDAPPA KALABURAGI 07/09/1930 01/06/1954 01/04/1972 04/04/1978 04/04/1978 30/09/1988 371(J) 2 R.H. SORTUR RAICHUR 19/04/1931 04/04/1955 01/01/1976 04/04/1978 04/04/1978 30/04/1989 371(J) 3 R.SRINIVASAIAH MYSURU 16/05/1926 15/04/1950 09/11/1972 13/04/1978 13/04/1978 31/05/1981 RETIRED RETIRED 4 B S SIDDRAJU MYSURU 15/12/1931 03/02/1956 17/11/1972 30/05/1978 30/05/1978 31/12/1989 SC 5 SRI. M.C. JAVALI DHARWAD 05/06/1925 10/06/1954 01/04/1972 31/08/1975 30/06/1978 30/06/1980 CASH CLERK 6 LAKSHMINARASIMAIAH B.N CCC, B'luru 01/01/1930 09/06/1958 09/06/1958 01/08/1978 01/08/1978 31/12/1987 7 BAYANNA.T.P CCC, B'luru 01/02/1923 20/10/1958 04/08/1975 01/08/1978 01/08/1978 31/01/1981 8 K.GUNDAPPA MANDYA 09/01/1928 12/09/1956 12/01/1967 16/08/1978 16/08/1978 31/01/1983 9 SRI.H.A.GURLHOSUR DHARWAD 08/10/1932 12/06/1956 01/04/1972 31/07/1977 31/08/1978 31/10/1990 SC CASH CLERK 10 RAMAKRISHNA B B KODAGU 08/10/1939 15/07/1959 21/10/1972 01/09/1978 01/09/1978 31/10/1997 EXPIRED WHILE IN SERVICE 11 G.V.
    [Show full text]
  • Nithish .P Original Research Paper Language Dr.Jagadish JR
    Original Research Paper Volume-7 | Issue-9 | September-2017 | ISSN - 2249-555X | IF : 4.894 | IC Value : 79.96 Language A STUDY ON THE IMPACT OF KANNADA NEWSPAPERS ON KERALA BORDERLINE KANNADIGAS Photographer/Artist Mangalore University Dakshinaa Kannada Managalore Karnataka Nithish .P India Dr.Jagadish JR Researcher University of Mysore Mysore Karnataka India KEYWORDS : . Introduction: Kahale' and 'Kasaragod Samachara' was published, after which 'Nada Newspapers have played a prominent role in imparting information Premi(1964)', 'Ajantha(1966)' and 'Lalitha(1966)' was published. and timely news before and after independence. Apparently, In the modern society no other media is as strong as the print media. Any The third phase began in the year 1980. By this time, almost 30 information which seems to be important is communicated through newspapers were published. In 1984 'Gilivindu' an evening newspaper newspaper. The history of newspaper is not only limited to the was started which lasted for several decades. In the same year, an broadcasting of Information and knowledge but also political, social, annual newspaper named 'Prathi Surya' was started in Kanhangad cultural and religious limitations. It is been acting as a watch dog of which was later shifted to Kasaragod. society to solve the problems of the people. The era of Kannada newspaper was started in 1843. A Christian Missionary father called by Main Kannada Newspapers name Harman Mogling published ever rst Kannada newspaper Prajavani called “Mangaluru Samachara.” The era of Kannada news papers Prajavani is one of the Kannada's famous daily newspapers. This which started then had greater development gradually . Today there are newspaper is very much popular in Dakshina Kannada.
    [Show full text]
  • Thomas Demand Roxana Marcoci, with a Short Story by Jeffrey Eugenides
    Thomas Demand Roxana Marcoci, with a short story by Jeffrey Eugenides Author Marcoci, Roxana Date 2005 Publisher The Museum of Modern Art ISBN 0870700804 Exhibition URL www.moma.org/calendar/exhibitions/116 The Museum of Modern Art's exhibition history— from our founding in 1929 to the present—is available online. It includes exhibition catalogues, primary documents, installation views, and an index of participating artists. MoMA © 2017 The Museum of Modern Art museumof modern art lIOJ^ArxxV^ 9 « Thomas Demand Thomas Demand Roxana Marcoci with a short story by Jeffrey Eugenides The Museum of Modern Art, New York Published in conjunction with the exhibition Thomas Demand, organized by Roxana Marcoci, Assistant Curator in the Department of Photography at The Museum of Modern Art, New York, March 4-May 30, 2005 The exhibition is supported by Ninah and Michael Lynne, and The International Council, The Contemporary Arts Council, and The Junior Associates of The Museum of Modern Art. This publication is made possible by Anna Marie and Robert F. Shapiro. Produced by the Department of Publications, The Museum of Modern Art, New York Edited by Joanne Greenspun Designed by Pascale Willi, xheight Production by Marc Sapir Printed and bound by Dr. Cantz'sche Druckerei, Ostfildern, Germany This book is typeset in Univers. The paper is 200 gsm Lumisilk. © 2005 The Museum of Modern Art, New York "Photographic Memory," © 2005 Jeffrey Eugenides Photographs by Thomas Demand, © 2005 Thomas Demand Copyright credits for certain illustrations are cited in the Photograph Credits, page 143. Library of Congress Control Number: 2004115561 ISBN: 0-87070-080-4 Published by The Museum of Modern Art, 11 West 53 Street, New York, New York 10019-5497 (www.moma.org) Distributed in the United States and Canada by D.A.P./Distributed Art Publishers, New York Distributed outside the United States and Canada by Thames & Hudson Ltd., London Front and back covers: Window (Fenster).
    [Show full text]